A $216 billion market is being built around the idea that your body is a system you can hack. That’s not a metaphor — it’s a business plan. And if you’re not paying attention to what biohacking is becoming, you’re going to wake up in a world you didn’t agree to.
According to new market analysis from Astute Analytica, the biohacking industry is projected to hit $216.68 billion by 2035, fueled by metabolic monitoring, wearable diagnostics, and personalized health optimization tools. That’s not a niche wellness trend anymore. That’s a full-blown industrial complex forming around your glucose levels, your sleep cycles, and your mitochondria.
What’s Actually Driving This
Forget the garage scientists injecting themselves with DIY CRISPR kits. That’s the sideshow. The real money is in three areas: continuous metabolic monitoring, next-generation wearables, and AI-driven personalization.
Continuous glucose monitors — devices like Dexterity, Levels, and the newly consumer-focused CGMs hitting shelves — are pulling in users who’ve never been diagnosed with diabetes. They just want to know how a burrito affects their blood sugar. Sounds quirky. It’s actually brilliant product design. Once you see your body’s data in real time, you can’t unsee it.
Wearables are getting sharper, too. We’re past counting steps. Devices now track heart rate variability, skin temperature, blood oxygen, and sleep architecture with enough accuracy that hospitals are starting to take the data seriously. The Oura Ring. The WHOOP band. Apple Watch’s creeping medicalisation. These aren’t toys. They’re early diagnostic infrastructure.
And then there’s the AI layer. Personalized health optimization means feeding your biometric data into algorithms that spit out recommendations — eat this, sleep at this time, take this supplement, do this workout. It sounds like a fitness app. It’s actually the beginning of on-demand, algorithm-managed personal medicine.
The People Already Living This
Go to any tech conference — the same world where Elon Musk appears in court at the start of cases that could reshape AI’s future — and you’ll find executives who haven’t eaten after 6pm in three years. They stack supplements like a poker hand. They have blood panels done quarterly. They wear glucose monitors despite having perfectly normal metabolic function. They are, functionally, their own clinical trial.
And here’s the thing — some of it works. Not all of it. A lot of it is expensive placebo wrapped in premium branding. But the core idea, that tracking your body’s systems and making small adjustments based on real data beats guessing, has genuine scientific legs.
The Class Problem Nobody Wants to Talk About
Here’s where it gets uncomfortable. Right now, biohacking is rich people’s medicine. A CGM subscription runs $200-plus a month. Functional medicine doctors who actually interpret your bloodwork? They don’t take insurance. High-quality sleep tracking hardware, personalized supplement stacks, cold plunge infrastructure — none of this is cheap.
The December 2025 US Tech Policy Roundup touched on how health technology regulation is still playing catch-up with what’s already in consumers’ hands. That gap matters here. Without policy guardrails, the best biohacking tools will stay locked behind premium paywalls while the mass market gets the watered-down version — a Fitbit telling you to take more steps while wealthy users get molecular-level metabolic coaching.
That’s not optimization. That’s stratification.
The Hot Take
Most biohackers aren’t optimizing their health. They’re managing anxiety. The obsessive tracking, the constant data-checking, the endless tweaking of sleep scores and HRV — for a significant chunk of users, this is health anxiety with a wearable strapped to it. The biohacking industry has done something genuinely clever: it’s taken a mental health problem, rebranded it as high performance, and built a $216 billion market around it. That’s not wellness. That’s a very expensive coping mechanism with great marketing.
Where This Goes From Here
The market projection to 2035 assumes acceleration. More sensors. Cheaper hardware. Deeper AI integration. Blood testing moving from labs to living rooms. Implantable devices edging into mainstream acceptance — Neuralink is the extreme version, but sub-dermal biosensors tracking real-time biomarkers aren’t science fiction. They’re on the product roadmap at multiple companies right now.
The same engineering ambition that puts SpaceX Falcon Heavy rockets on launch pads is now pointed at the human body. Same mindset. Same appetite for iteration. Same willingness to treat existing systems as problems to be engineered around.
The question isn’t whether biohacking becomes mainstream — it already is. The question is who controls the data, who can afford the good stuff, and whether the industry builds tools that genuinely extend healthy human life or just sells expensive mirrors to people who were already healthy. The next ten years will answer that. Pay attention now, while you still have a say in how it goes.